^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
377 - Molecular features-based model for predicting benefit from Bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor
Published date:
03/10/2021
Excerpt:
A total of 176 patients with EGFR-mutant stage IIIB-IV relapsed or metastatic NSCLC and received first-generation EGFR-TKI gefitinib or erlotinib monotherapy (T; n=88) or combined with bevacizumab (A+T; n=88)...As compared to the T group, progression-free survival (PFS) was significantly longer among patients who received A+T and harbored concurrent EGFR amplification (16.1 vs 9.0 months; HR: 0.267, 95%CI: 0.110-0.651; p=0.004), and hotspot and loss-of-function mutations in TP53 (16.1 vs 8.0 months; HR: 0.215, 95%CI: 0.108-0.426; p<0.001).
